Sign in to add mentor
Richard G. Moran grad student 1989 (Cell Biology Tree)
 (Thesis:"Tumor cell responses to inhibition of thymidylate synthase")
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lee H, Horbath A, Kondiparthi L, et al. (2024) Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance. Nature Communications. 15: 79
Lulla AR, Akli S, Karakas C, et al. (2023) Neutrophil elastase remodels mammary tumors to facilitate lung metastasis. Molecular Cancer Therapeutics
Wingate HF, Keyomarsi K. (2023) Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All. Cancer Research. 83: 3165-3167
Navarro-Yepes J, Kettner NM, Rao X, et al. (2023) Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Cancer Research
DiPeri TP, Evans KW, Raso MG, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Haddad TC, Suman VJ, D'Assoro AB, et al. (2023) Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. Jama Oncology
Nguyen TDT, Wang Y, Bui TN, et al. (2023) Sequential targeting of retinoblastoma and DNA synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real-time. Cancer Research
Li M, Tsavachidis S, Wang F, et al. (2022) Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. Oncogene
Li H, Wang Y, Lin K, et al. (2022) CHD1 promotes sensitivity to Aurora kinase inhibitors by suppressing interaction of AURKA with its coactivator TPX2. Cancer Research
Luo L, Keyomarsi K. (2022) PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opinion On Investigational Drugs. 31: 607-631
See more...